Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Holding DXCM?
Track your performance easily
DXCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.34 - $142.00
Previous Close$68.61
Volume1.71M
Average Volume (3M)4.34M
Market Cap
$26.76B
Enterprise Value$28.71B
Total Cash (Recent Filing)$621.20M
Total Debt (Recent Filing)$2.53B
Price to Earnings (P/E)41.1
Beta0.95
Next Earnings
Feb 06, 2025EPS Estimate
$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding390,595,390
10 Day Avg. Volume5,533,979
30 Day Avg. Volume4,338,266
Standard Deviation0.15
R-Squared0.16
Alpha0.00727
Financial Highlights & Ratios
Price to Book (P/B)13.61
Price to Sales (P/S)6.89
Price to Cash Flow (P/CF)34.10
P/FCF Ratio74.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.26
Enterprise Value/Gross Profit12.54
Enterprise Value/Ebitda29.50
Forecast
1Y Price Target
$96.24Price Target Upside40.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Dexcom News
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityDXCM exited September with $2.49B in cash, cash equivalents and marketable securities and with its revolving credit facility undrawn, giving the company great flexibility as it continues to expand its production capacity and evaluate new opportunities.
International GrowthInternational revenue of $292M grew 16% year-over-year organically and exceeded projected and Street expectations, with Japan starting to contribute to sustainable growth.
Product Pipeline ProgressDXCM launched new products like Stelo OTC, G7 in Australia, and Dexcom ONE+ in France, indicating strong product pipeline progress.
Bears Say
Market Share And CompetitionDXCM lost incremental market share in the DME channel vs. 2Q24, contributing to a 2% y/y decline in revenue in the US.
Product OfferingsAbbott is more flexible on purchase options with three purchasing options while Dexcom is only offering two purchase options.
Revenue DeclineA larger-than-expected decline in U.S. revenue per patient contributed to the underperformance.
---
Ownership Overview
0.48% Insiders
32.39% Mutual Funds
7.13% Other Institutional Investors
33.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 06, 2025 which is in 91 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 24, 2024. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.435 by $0.015.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.52.
How many shares outstanding does Dexcom have?
Dexcom has 390,595,400 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.45 in its last earnings report, beating expectations of $0.435. Following the earnings report the stock price went down -1.884%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 1B.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.24 (40.50% Upside)
$96.24 (40.50% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 687.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.65%
12-Months-Change
Fundamentals
Return on Equity
32.06%
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q3 2024
0:00 / 0:00
---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$96.24
▲(40.50% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
32/46 ratings generated profit
1 Year Average Return
+37.40%
assigned a buy rating 14 days ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +37.40% per trade.
---